Cemtrex Stock Climbs as FY Revenue Rises

Dow Jones2025-12-30

By Kelly Cloonan

 

Shares of Cemtrex rose after the company posted higher revenue in its latest fiscal year, driven by growth in both its segments.

The stock climbed 33% to $2.81 in after-hours trading on Monday. Through market close, shares are down 95% this year.

The technology company posted a loss of $28.3 million for the year ended Sept. 30, compared with a loss of $7.6 million a year earlier.

Revenue rose to $76.5 million from $66.9 million the year prior.

In the company's security segment, revenue climbed 20%, boosted by enterprise and government customers. Industrial services revenue similarly rose, up 9%, due to sustained demand across manufacturing, infrastructure and industrial end markets.

The results mark a return to positive operating profit, Chief Executive Saagar Govil. The company expects further improvement in its core operating performance going forward, given certain expenses included in the recent results are not expected to recur, Govil said.

"With the core business now profitable, our focus shifts to scaling operating leverage," Govil said.

 

Write to Kelly Cloonan at kelly.cloonan@wsj.com

 

(END) Dow Jones Newswires

December 29, 2025 17:56 ET (22:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment